PIPasquale Iacopino

Pasquale Iacopino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pasquale Iacopino has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Giuseppe Irrera

    Centro Unico Regionale Trapianti Midollo Osseo e Terapie Cellulari “Alberto Neri,” Azienda Ospedaliera “Bianchi-Melacrino-Morelli”, 89100 Reggio Calabria, Italy

    3 shared publications
  • Attilio Guarini

    Hematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy

    2 shared publications
  • Caterina Stelitano

    Hematology Unit, Azienda Ospedaliera “Bianchi‐Melacrino‐Morelli,” Reggio Calabria, Italy

    2 shared publications
  • Giuseppe Console

    Bone Marrow Transplant Unit, Azienda Ospedaliera “Bianchi‐Melacrino‐Morelli,” Reggio Calabria, Italy

    2 shared publications
  • Massimo Martino

    Hematology and Stem Cell Transplantation and Cellular Rerapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Presidio Morelli, 89121 Reggio Calabria, Italy

    2 shared publications
  • Vincenzo Callea

    Hematology Unit, Azienda Ospedaliera “Bianchi‐Melacrino‐Morelli,” Reggio Calabria, Italy

    2 shared publications

Latest Publications

  • Open Access

    Challenges and Opportunities of MicroRNAs in Lymphomas

    by Giacoma De Tullio, Vincenza De Fazio, Nicola Sgherza, Carla Minoia, Simona Serratì, Francesca Merchionne, Giacomo Loseto, Angela Iacobazzi, Antonello Rana, Patrizia Petrillo, et al.

    MicroRNAs (miRNAs) are small non-coding RNAs that control the expression of many target messenger RNAs (mRNAs) involved in normal cell functions (differentiation, proliferation and apoptosis). Consequently their aberrant expression and/or functions are related to pathogenesis of many human diseases including cancers. Haematopoiesis is a highly regulated process controlled by a complex network of molecular mechanisms that simultaneously regulate commitment, differentiation, proliferation, and apoptosis of hematopoietic stem cells (HSC). Alterations on this network could affect the normal haematopoiesis, leading to the development of haematological malignancies such as lymphomas. The incidence of lymphomas is rising and a significant proportion of patients are refractory to standard therapies. Accurate diagnosis, prognosis and therapy still require additional markers to be used for diagnostic and prognostic purpose and evaluation of clinical outcome. The dysregulated expression or function of miRNAs in various types of lymphomas has been associated with lymphoma pathogenesis. Indeed, many recent findings suggest that almost all lymphomas seem to have a distinct and specific miRNA profile and some miRNAs are related to therapy resistance or have a distinct kinetics during therapy. MiRNAs are easily detectable in fresh or paraffin-embedded diagnostic tissue and serum where they are highly stable and quantifiable within the diagnostic laboratory at each consultation. Accordingly they could be specific biomarkers for lymphoma diagnosis, as well as useful for evaluating prognosis or disease response to the therapy, especially for evaluation of early relapse detection and for greatly assisting clinical decisions making. Here we summarize the current knowledge on the role of miRNAs in normal and aberrant lymphopoiesis in order to highlight their clinical value as specific diagnosis and prognosis markers of lymphoid malignancies or for prediction of therapy response. Finally, we discuss their controversial therapeutic role and future applications in therapy by modulating miRNA.


  • Open Access

    Type 2 diabetes mellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood

    by Marco F. Lombardo, Pasquale Iacopino, Maria Cuzzola, Elisa Spiniello, Cristina Garreffa, Francesca Ferrelli, Andrea Coppola, Riccardo Saccardi, Alberto Piaggesi, Rosanna Piro, et al.

    Type 2 diabetes mellitus (T2DM) is associated with endothelial dysfunction, which leads to vascular complications. Endothelial progenitor cells (EPCs) are thought to be a subset of cells derived from the bone marrow that play a crucial role in the neovascularization of ischemic tissue and in the maintenance of endothelial cell integrity. In contrast, circulating endothelial cells (CECs) are of endothelial origin and become detached from the intima of blood vessels in response to pathological stimuli. The study investigated the effects of T2DM on subpopulations of EPCs and CECs in peripheral blood, as compared with the effects on unacylated (UAG) and acylated (AG) ghrelin levels, which have been shown recently to play an important role in endothelial dysfunction associated with diabetes. Using the high‐performance flow cytometer FACSCanto, and UAG/AG ghrelin enzyme immunoassay kits, we analyzed whole peripheral blood samples from: (i) diabetic patients with a history of disease of less than 1 year and no clinical evidence of angiopathy, (ii) diabetic patients with long‐standing disease with vascular complications, and (iii) healthy donors. We found that T2DM did not affect bone‐marrow mobilization, but it altered the UAG/AG profile and decreased the number of highly differentiated EPCs (late EPCs) greatly. In addition, T2DM increased the number of CECs, together with the number of activated CECs. Our results suggest that: (i) the endothelial damage could be due mainly to altered maturation/commitment of EPCs, rather than a simple decrease in their production in the bone marrow; and (ii) EPC subpopulations and ghrelin levels could be useful markers to assess endothelial damage in diabetes. © 2012 International Society for Advancement of Cytometry


  • We have a specific duty to maximise the safety of related donors

    by Pasquale Iacopino, Attilio Guarini

  • High‐dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients

    by Massimo Martino, Giuseppe Console, Giuseppe Irrera, Giulia Praticò, Caterina Stelitano, Vincenzo Callea, Fortunato Morabito, Eugenia Quartarone, Caterina Musolino, Eugenio Piro, et al.

    The recent development of reduced intensity conditioning and allotransplantation (RICT) has opened a new way to assure engraftment of donor cells while reducing early transplant‐related mortality. We evaluated the combination of high‐dose therapy and autologous peripheral blood stem cells transplantation (APBSCT) followed by RICT to extend the benefit of allografting procedures in de novo multiple myeloma (MM) patients. Fifteen subjects with stage III MM (median age 51 years, range 40–57) received high dose melphalan (200 mg/m2) followed by APBSCT previously collected after cyclophosphamide (4 g/m2) and granulocyte colony‐stimulating factor (G‐CSF). After 3–4 months from APBSCT, the patients underwent RICT, consisting of fludarabine 30 mg/m2 + cyclophosphamide 300 mg/m2 on days −4, −3, and −2. Acute graft‐versus‐host disease (GVHD) occurred in 2 patients; 6 patients developed chronic GVHD; 4 patients developed CMV antigenemia and were treated pre‐emptively with ganciclovir. No transplant related mortality was shown. Response was simultaneously measured by both electrophoresis (EP) and immunofixation (IF); when IF was negative, patients were classified in complete remission (CR) and when it remained positive, near CR (nCR). After a median follow up of 44 months post APBSCT, 100 and 43% of patients are still alive and progression‐free, respectively. Overall, the CR + nCR rate after dose‐reduced allograft was enhanced from 26.7 to 73.3%. A correlation not statistically significant between GVHD and remission was found. In conclusion, an up‐front tandem strategy with a very low reduced intensity‐conditioning regimen for allografting following autografting is feasible and induces high CR/nCR rate in MM. Am. J. Hematol., 2006.


    • 1 November 2002
      • Vol. 87  (11) , 1192-9

    Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma.

    by Fortunato Morabito, Massimo Martino, Caterina Stelitano, Esther Oliva, Mariagrazia Kropp, Giuseppe Irrera, Giuseppe Console, Mohamed Fujo, Giuseppe Messina, Stefano Molica, et al.

    A progressively growing number of peripheral blood stem cell transplants (PBSCTs) are being performed in patients with newly diagnosed multiple myeloma (MM) since they are ever more frequently being offered as up-front therapy. Furthermore, there are considerable concerns regarding the appropriate use of health care resources in order to reduce costs associated with PBSCT. One of the strategies attempted to reach this goal is outpatient-based PBSCT. The aim of this study was to analyze the feasibility of a mixed inpatient-outpatient model (MIOM) for MM patients receiving high-dose melphalan, and homogeneously undergoing autologous PBSCT, antimicrobial and antiviral prophylaxis and post-transplant growth factor treatment. Furthermore, we retrospectively compared results of the MIOM with those of the traditional total inpatient model (TIM). MIOM was applied for 60 transplants in a total of 29 MM patients. Results were compared with retrospective data concerning the traditional TIM for 40 transplants (27 MM patients). MIOM cases were older than TIM ones (55.3 6.3 years vs 49.6 9.2 years, p=0.01), but were comparable for sex and disease status. Granulocyte recovery time was shorter in the MIOM group (9.0 0.7 vs 9.7 1.2 days, p=0.004), while a similar number of stem cells were infused. There was no difference in platelet engraftment. The number of episodes and duration of grade II-IV mucositis were similar in both groups. Fever occurred in fewer MIOM cases (25% v 51.6%, p=0.02), while its duration was similar. In multivariate analysis, mucositis (grades II-IV) was the sole independent predictor of fever development (p=0.002). Half of the MIOM cases never required re-admission, 26 were re-admitted (median hospital stay 9 days) and 4 cases were not discharged (median hospital stay 15 days). The median time to discharge of TIM cases was 20 days. Non-hematologic toxicities were low in both groups. Since outpatient management and liberal hospitalization criteria have resulted in safe conduct of MIOM transplants, this program can be safely offered to MM patients.